POTASSIUM ACETATE (potassium acetate) by Pfizer is clinical pharmacology as the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. First approved in 1984.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
Potassium acetate is an intravenous electrolyte replacement therapy that restores intracellular and serum potassium levels in hypokalemic patients. It functions as a potassium source while acetate serves as a hepatically metabolized bicarbonate precursor, making it suitable even in severe liver disease. The drug addresses critical electrolyte imbalances in hospital and critical care settings.
As a decades-old generic injectable approaching LOE, this product faces high competitive pressure (30% rated) with minimal growth trajectory and likely small, maintenance-focused commercial teams.
CLINICAL PHARMACOLOGY As the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. The normal potassium concentration in the intracellular fluid compartment is about 160 mEq/liter. The normal serum potassium range is 3.5 to 5.0 mEq/liter.…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on potassium acetate offers limited career growth within a mature, commoditized market; roles are primarily focused on cost management, hospital relationships, and operational efficiency rather than brand building or clinical innovation. This is a stable but non-strategic product suitable for early-career professionals seeking hands-on experience in generic or hospital-channel operations.
Worked on POTASSIUM ACETATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo